Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr. Reddy's Looks To Acquire U.S. Generics Company Following $115 Mil. IPO

Executive Summary

Dr. Reddy's Laboratories plans to expand its presence in the U.S. generics market through acquisitions following its April 11 initial public offering.

You may also be interested in...



Par Aims To Add Branded Products After Merck KGaA Divests Equity Stake

Par is looking to add branded products to its portfolio as it seeks to join the top-tier independent generic drug companies after Merck KGaA divests its controlling interest in the firm.

Par Aims To Add Branded Products After Merck KGaA Divests Equity Stake

Par is looking to add branded products to its portfolio as it seeks to join the top-tier independent generic drug companies after Merck KGaA divests its controlling interest in the firm.

Par Generic Fluoxetine Expected To Launch In Three Strengths On Aug. 2

Par plans to launch 10 mg, 20 mg and 40 mg strengths of fluoxetine Aug. 2 following the expiry of Lilly's pediatric exclusivity for Prozac.

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel